Seminars in Nuclear Medicine
Volume 34, Issue 3 , Pages 209-223 , July 2004

PET and PET-CT for evaluation of colorectal carcinoma

  • Dominique Delbeke

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN, USA
    • Corresponding Author InformationAddress reprint requests to Dominique Delbeke, MD, PhD, Professor and Director of Nuclear Medicine and PET, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, 21st Avenue South and Garland, Nashville, TN 37232-2675 USA
    • ,
  • William H Martin

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN, USA

References 

  1. Delbeke D, Martin WH, Patton JA, et al.  Practical FDG Imaging (A teaching file). New York, New York: Springer Verlag; 2002;
  2. Warburg O. Versuche und uberledbeudem carcinomgewebe (methoden). Biochem Z. 1923;142:317–333
  3. Flier JS, Mueckler MM, Usher P, et al.  Elevated levels of glucose transport and transporter messenger RNA are induced by rats or src oncogenes. Science. 1987;235:1492–1495
  4. Monakhov NK, Neistadt EI, Shaylovskii MM, et al.  Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst. 1978;61:27–34
  5. Knox WE, Jamdar SC, Davis PA. Hexokinase, differentiation, and growth rates of transplanted tumors. Cancer Res. 1970;30:2240–2244
  6. Som P, Atkins HL, Bandoypadhayay D, et al.  A fluorinated glucose analog, 2-fluoro-2-deoxy-2-D-glucose [18F] (Nontoxic tracer for rapid tumor detection). J Nucl Med. 1980;21:670–675
  7. Gallagher BM, Fowler JS, Gutterson NI, et al.  Metabolic trapping as a principle of radiopharmaceutical design (Some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-D-glucose). J Nucl Med. 1978;19:1154–1161
  8. Cook GJR, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning (Potential for error in interpretation). Semin Nucl Med. 1996;26:308–314
  9. Engel H, Steinert H, Buck A, et al.  Whole body PET (Physiological and artifactual fluorodeoxyglucose accumulations). J Nucl Med. 1996;37:441–446
  10. Hutton BF, Braun M. Software for image registration (Algorithms, accuracy, efficacy). Semin Nucl Med. 2003;33:180–192
  11. Townsend DW, Beyer T, Bloggett TM. PET/CT scanners (A hardware approach to image fusion). Semin Nucl Med. 2003;33:193–204
  12. Bakheet SM, Powe J. Benign causes of 18-FDG uptake on whole body imaging. Semin Nucl Med. 1998;28:352–358
  13. Cohade C, Osman M, Pannu HK, et al.  Uptake in supraclavicular area fat (“USA-Fat”) (description on 18F-FDG PET/CT). J Nucl Med. 2003;44:170–176
  14. Kamel EM, Goerres GW, Burger C, et al.  Recurrent laryngeal nerve palsy in patients with lung cancer (Detection with PET-CT image fusion-Report od six cases). Radiology. 2002;224:153–156
  15. Kubota R, Yamada S, Kubota K, et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo (high accumulation in macrophages and granulocytes studied by microautoradiography). J Nucl Med. 1992;33:1972–1980
  16. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET (Correlation with histopathologic and CT findings). Radiology. 1998;206:755–760
  17. Mukai M, Sadahiro S, Yasuda S, et al.  Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep. 2000;7:85–87
  18. Kantorova I, Lipska L, Belohlavek O, et al.  Routine 18F-FDG PET preoperative staging of colorectal cancer (Comparison with conventional staging and its impact on treatment decision making). J Nucl Med. 2003;44:1784–1788
  19. Yasuda S, Fujii H, Nakahara T, et al.  18F-FDG PET detection of colonic adenomas. J Nucl Med. 2001;42:989–992
  20. August DA, Ottow RT, Sugarbaker PH. Clinical perspectives on human colorectal cancer metastases. Cancer Metastases Rev. 1984;3:303–324
  21. Foster JH, Lundy J. Liver metastases. Curr Probl Surg. 1981;18:158–202
  22. Holm A, Bradley E, Aldrete J. Hepatic resection of metastases from colorectal carcinoma (morality, morbidity and pattern of recurrence). Ann Surg. 1989;209:428–434
  23. Hughes KS, Simon R, Songhorabodi S, et al.  Resection of liver for colorectal carcinoma metastases (a multi-institutional study of indications for resection). Surgery. 1988;103:278–288
  24. Moertel CG, Fleming TR, McDonald JS, et al.  An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943–947
  25. Chen YM, Ott DJ, Wolfman NT, et al.  Recurrent colorectal carcinoma (Evaluation with barium enema examination and CT). Radiology. 1987;163:307–310
  26. Sugarbaker PH, Grianola FJ, Dwyer S, et al.  A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery. 1987;102:79–87
  27. Steele G, Bleday R, Mayer R, et al.  A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver (Gastrointestinal Tumor Study Group protocol 6584). J Clin Oncol. 1991;9:1105–1112
  28. Granfield CAJ, Charnsangaveg C, Dubrow RA, et al.  Regional lymph node metastases in carcinoma of the left side of the colon and rectum (CT demonstration). AJR. 1992;159:757–761
  29. Charnsangavej C, Whitley NO. Metastases to the pancreas and peripancreatic lymph nodes from carcinoma of the right colon (CT findings in 12 patients). AJR. 1993;160:49–52
  30. McDaniel KP, Charnsangavej C, Dubrow R, et al.  Pathways of nodal metastases in carcinoma of the cecum, ascending colon and transverse colon (CT demonstration). AJR. 1993;161:61–64
  31. Soyer P, Levesque M, Elias D, et al.  Detection of liver metastases from colorectal cancer (comparison of intraoperative US and CT during arterial portography). Radiology. 1992;183:541–544
  32. Nelson RC, Chezmar JL, Sugarbaker PH, et al.  Hepatic tumors (comparison of CT during arterial portography, delayed CT and MR imaging for preoperative evaluation). Radiology. 1989;172:27–34
  33. Small WC, Mehard WB, Langmo LS, et al.  Preoperative determination of the resectability of hepatic tumors (efficacy of CT during arterial portography). AJR. 1993;161:319–322
  34. Peterson MS, Baron RL, Dodd GD, et al.  Hepatic parenchymal perfusion detected with CTPA (imaging-pathologic correlation). Radiology. 1992;183:149–155
  35. Yonekura Y, Benua RS, Brill AB, et al.  Increased accumulation of 2-deoxy-2[18F]fluoro-D- glucose in liver metastases from colon carcinoma. J Nucl Med. 1982;23:1133–1137
  36. Strauss LG, Clorius JH, Schlag P, et al.  Recurrence of colorectal tumors (PET evaluation). Radiology. 1989;170:329–332
  37. Ito K, Kato T, Tadokoro M, et al.  Recurrent rectal cancer and scar (Differentiation with PET and MR imaging). Radiology. 1992;182:549–552
  38. Kim EE, Chung SK, Haynie TP, et al.  Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG-PET. Radiographics. 1992;12:269–279
  39. Gupta NC, Falk PM, Frank AL, et al.  Pre-operative staging of colorectal carcinoma using positron emission tomography. Nebr Med J. 1993;78:30–35
  40. Falk PM, Gupta NC, Thorson AG, et al.  Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum. 1994;37:153–156
  41. Beets G, Penninckx F, Schiepers C, et al.  Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg. 1994;81:1666–1670
  42. Schiepers C, Penninckx F, De Vadder N, et al.  Contribution of PET in the diagnosis of recurrent colorectal cancer (Comparison with conventional imaging). Eur J Surg Oncol. 1995;21:517–522
  43. Vitola JV, Delbeke D, Sandler MP, et al.  Positron emission tomography to stage metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21–26
  44. Lai DT, Fulham M, Stephen MS, et al.  The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer. Arch Surg. 1996;131:703–707
  45. Delbeke D, Vitola J, Sandler MP, et al.  Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196–1201
  46. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al.  Detection of recurrent and metastatic colorectal cancer (comparison of positron emission tomography and computed tomography). Ann Surg Oncol. 1997;4:613–620
  47. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al.  Utility of FDG PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227:319–323
  48. Valk PE, Abella-Columna E, Haseman MK, et al.  Whole-body PET imaging with F-18-fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503–511
  49. Ruhlmann J, Schomburg A, Bender H, et al.  Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum. 1997;40:1195–1204
  50. Flamen P, Stroobants S, Van Cutsem E, et al.  Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol. 1999;17:894–901
  51. Akhurst T, Larson SM. Positron emission tomography imaging of colorectal cancer. Semin Oncol. 1999;26:577–583
  52. Vogel SB, Drane WE, Ros PR, et al.  Prediction of surgical resectability in patients with hepatic colorectal metastases. Ann Surg. 1994;219:508–516
  53. Imbriaco M, Akhurst T, Hilton S, et al.  Whole-Body FDG-PET in patients with recurrent colorectal carcinoma. A comparative study with CT. Clin Positron Imaging. 2000;3:107–114
  54. Imdahl A, Reinhardt MJ, Nitzsche EU, et al.  Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Arch Surg. 2000;385:129–134
  55. Staib L, Schirrmeister H, Reske SN, et al.  Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?. Am J Surg. 2000;180:1–5
  56. Kalff VV, Hicks R, Ware R. F-18 FDG PET for suspected or confirmed recurrence of colon cancer. A prospective study of impact and outcome. Clin Pos Imaging. 2000;3:183
  57. Whiteford MH, Whiteford HM, Yee LF, et al.  Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000;43:759–767 discussion 767–770
  58. Berger KL, Nicholson SA, Dehadashti F, et al.  FDG PET evaluation of mucinous neoplasms (correlation of FDG uptake with histopathologic features). Am J Roentgenol. 2000;174:1005–1008
  59. Kinkel K, Lu Y, Both M, et al.  Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET) (A meta-analysis). Radiology. 2002;224:748–756
  60. Huebner RH, Park KC, Shepherd JE, et al.  A meta-analysis of the literature for whole-body FDG PET detection of colorectal cancer. J Nucl Med. 2000;41:1177–1189
  61. Gambhir SS, Czernin J, Schimmer J, et al.  A tabulated review of the literature. J Nucl Med. 2001;42(suppl):9S–12S
  62. Meltzer CC, Martinelli MA, Beyer T, et al.  Whole-body FDG PET imaging in the abdomen (Value of combined PET-CT). J Nucl Med. 2001;42:35P
  63. Meltzer CC, Makhija S, Howden N, et al.  PET/CT in recurrent ovarian and fallopian tube carcinoma. J Nucl Med. 2001;42:284P
  64. Cohade C, Osman M, Leal J, et al.  Direct comparison of FDG PET and PET-CT imaging in colorectal carcinoma. J Nucl Med. 2003;44:1797–1803
  65. Antoch G, Freudenberg LS, Egeldorf T, et al.  Focal tracer uptake (A potential artifact in contrasted-enhanced dual-modality PET/CT scans). J Nucl Med. 2002;43:1339–1342
  66. Dizendorf E, Hany TF, Buck A, et al.  Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med. 2003;44:732–738
  67. Cohade C, Osman M, Nakamoto Y, et al.  Initial experience with oral contrast in PET/CT (Phantom and clinical studies). J Nucl Med. 2003;44:412–416
  68. Goerres GW, Hany TF, Kamel E, et al.  Head and neck imaging with PET/CT (Artifacts from dental metallic implants). Eur J Nucl Med Mol Imaging. 2002;29:367–370
  69. Nakamoto Y, Osman M, Cohade C, et al.  PET-CT (comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images). J Nucl Med. 2002;43:1137–1143
  70. Strasberg SM, Dehdashti F, Siegel BA, et al.  Survival of patients evaluated by FDG PET before hepatic resection for metastatic colorectal carcinoma (A prospective database study). Ann Surg. 2001;233:320–321
  71. Ruers TJ, Langenhoff BS, Neeleman N, et al.  Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases (A prospective study). J Clin Oncol. 2002;20:388–395
  72. Meta J, Seltzer M, Schiepers C, et al.  Impact of 18F-FDG PET on managing patients with colorectal cancer (The referring physicians’ perspective). J Nucl Med. 2001;42:586–590
  73. Alyafei S, Inoue T, Zhang H, et al.  Image fusion using PACS for MRI, CT, and PET images. Clin Pos Imaging. 1999;2:137–143
  74. Israel O, Mor M, Guralnik L, et al.  The new technology of combined transmission and emission F-18 FDG tomography (FDG-TET) in the diagnosis and management of cancer patients. Clin Pos Imaging. 2000;3:143
  75. Delbeke D, Martin WH, Patton JA, et al.  Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and x-ray-based attenuation maps. Radiology. 2001;218:163–171
  76. Martinelli M, Townsend D, Meltzer C, et al.  Survey of Results of whole body imaging using the PET/CT at the University of Pittsburgh Medical Center PET facility. Clin Pos Imaging. 2000;3:161
  77. Yeung HW, Schoder H, Larson SM. Utility of PET/CT for assessing equivocal PET lesions in oncology—initial experience. J Nucl Med. 2002;43:32P
  78. Dizendorf E, Ciernik IF, Baumert B, et al.  Impact of integrated PETCT scanning on external beam radiation treatment planning. J Nucl Med. 2002;43:33P
  79. Ciernik IF, Dizendorf E, Baumert BG, et al.  Radiation treatment planning with integrated positron emission and computed tomography (PET/CT) (A feasibility study). Int J Radiat Oncol Biol Phys. 2003;57:853–863
  80. Charron M, Beyer T, Bohnen NN, et al.  Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med. 2000;25:905–910
  81. Bar-Shalom R, Yefremov N, Guralnik L, et al.  Clinical performance of PET/CT in the evaluation of cancer (Additional value for diagnostic imaging and patient management). J Nucl Med. 2003;44:1200–1209
  82. Roman CD, Delbeke D. Incremental diagnostic value of fusion imaging with integrated PET-CT in oncology compared to PET alone. 2003; RSNA Scientific Program 487
  83. Osman MM, Cohade C, Fishman E, et al.  Clinically significant incidental findings on non-contrast CT portion of PET-CT studies (Frequency in 250 patients). J Nucl Med. 2002;43:307P
  84. Gambhir SS, Valk P, Shepherd J, et al.  Cost effective analysis modeling of the role of FDG-PET in the management of patients with recurrent colorectal cancer. J Nucl Med. 1997;38:90P
  85. Park KC, Schwimmer J, Sheperd JE, et al.  Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg. 2001;233:310–319
  86. Bertino JR. Biomodulation of 5-fluorouracil with antifolates. Semin Oncol. 1997;24(suppl):S18–S56
  87. Strauss LG, Clorius JH, Schlag P, et al.  Recurrence of colorectal tumors (PET evaluation). Radiology. 1989;170:329–332
  88. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al.  PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med. 1991;31:1485–1490
  89. Moore HG, Akhurst T, Larson SM, et al.  A case controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg. 2003;197:22–28
  90. Guillem J, Calle J, Akhurst T, et al.  Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-Fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000;43:18–24
  91. Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol. 2003;9:193–200
  92. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002;38:1023–1033
  93. Gray B, Van Hazel G, Hope M, et al.  Randomized trial of Sir-spheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711–1720
  94. Nijsen JF, van het Schip AD, Hennink WE, et al.  Advances in nuclear oncology (microspheres for internal radionuclide therapy of liver tumours). Curr Med Chem. 2002;9:73–82
  95. Findlay M, Young H, Cunningham D, et al.  Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases (correlation with tumor response to fluorouracil). J Clin Oncol. 1996;14:700–708
  96. Vitola JV, Delbeke D, Meranze SG, et al.  Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer. 1996;78:2216–2222
  97. Torizuka T, Tamaki N, Inokuma T,et al: Value of fluorine-18-FDG PET to monitor hepatocellular carcinoma after interventional therapy.
  98. Langenhoff BS, Oyen WJ, Jager GJ, et al.  Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases (A prospective study). J Clin Oncol. 2002;20:4453–4458
  99. Anderson GS, Brinkmann F, Soulen MC, et al.  FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med. 2003;28:192–197
  100. Ludwig V, Hopper OW, Martin WH, et al.  FDG-PET surveillance of hepatic metastases from prostate cancer following radiofrequency ablation—Case report. Am Surg. 2003;69:593–598
  101. Wong CY, Salem R, Raman S, et al.  Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET (a comparison with CT or MRI). Eur J Nucl Med Mol Imag. 2002;29:815–820
  102. Tatlidil R, Jadvar H, Bading JR, et al.  Incidental colonic fluorodeoxyglucose uptake (correlation with colonoscopic and histopathologic findings). Radiology. 2002;224:783–787
  103. Blau M, Nagler W, Bender MA. A new isotope for bone scanning. J Nucl Med. 1962;3:332–334
  104. Bang S, Baug CA. Topographical distribution of fluoride in iliac bone of a fluoride-treated osteoporotic patient. J Bone Miner Res. 1990;5:S87–S89
  105. Schirrmeister H, Gulhman A, Elsner K, et al.  Sensitivity in detecting osseous lesions depends on anatomic location (planar scintigraphy versus 18F PET). J Nucl Med. 1999;40:1623–1629
  106. Schirrmeister H, Gulhman A, Kotzerke J, et al.  Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381–2389
  107. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine, and thymidine as agents to monitor early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med. 1993;34:773–780
  108. Reinhardt MJ, Kubota K, Yamada S, et al.  Assessment of cancer recurrence in residual tumors after fractionated radiotherapy (A comparison of fluorodeoxyglucose, L-methionine and thymidine). J Nucl Med. 1997;38:280–287
  109. Shields AF, Grierson JR, Dohmen BM, et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  110. Dittman H, Dohman BM, Paulsen F. [(18)F]FLT PET for diagnosis and staging of thoracic tumors. Eur J Nucl Med Mol Imaging. 2003;30:1407–1412
  111. Francis DL, Visvikis D, Costa DC, et al.  Potential impact of [(18)F]3′-deoxy-3′-fluorothymidine versus [(18)F]fluoro- 2-deoxy-d-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Imaging. 2003;30:988–994
  112. Kissel J, Brix G, Bellemann ME, et al.  Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res. 1997;57:3415–3423
  113. Moelher M, Dimitrakopoulou-Strauss A, Gutzler F, et al.  18F-fluorouracil positron emission tomography and the prognosis of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer. 1998;83:245–253
  114. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, et al.  Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med. 1998;39:1197–1202

PII: S0001-2998(04)00024-8

doi: 10.1053/j.semnuclmed.2004.03.006

Seminars in Nuclear Medicine
Volume 34, Issue 3 , Pages 209-223 , July 2004

Article Tools

* Image Usage & Resolution